Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,021 Cr
Revenue (TTM)
₹466 Cr
Net Profit (TTM)
₹49 Cr
ROE
9.3 %
ROCE
11.1 %
P/E Ratio
40.9
P/B Ratio
5.9
Industry P/E
38.59
EV/EBITDA
28.3
Div. Yield
0 %
Debt to Equity
0
Book Value
₹3.6
EPS
₹0.5
Face value
1
Shares outstanding
940,000,000
CFO
₹51.69 Cr
EBITDA
₹199.65 Cr
Net Profit
₹158.98 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syncom Form
| 7.5 | 30.8 | 37.4 | 69.8 | -- | -- | -- |
|
BSE Healthcare
| -2.6 | 5.8 | 11.7 | 19.7 | 25.9 | 22.2 | 11.0 |
|
BSE Small Cap
| -2.6 | 9.6 | 21.0 | 6.2 | 27.3 | 35.1 | 17.6 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Syncom Form
| 27.0 | 70.1 |
|
BSE Small Cap
| 29.0 | 47.5 |
|
BSE Healthcare
| 43.1 | 37.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syncom Form
|
21.5 | 2,021.0 | 466.0 | 49.4 | 10.7 | 15.1 | 40.9 | 5.9 |
| 695.5 | 2,016.8 | 451.8 | 50.8 | 11.4 | 16.3 | 39.7 | 6.2 | |
| 475.9 | 7,752.2 | 2,108.1 | 266.8 | 12.5 | 11.7 | 29.1 | 3.4 | |
| 370.7 | 3,729.3 | 819.8 | 69.7 | 13.9 | 11.9 | 53.5 | 6.2 | |
| 451.0 | 2,767.3 | 559.1 | -8.7 | -10.9 | -159 | -- | 3.3 | |
| 5,831.0 | 9,692.5 | 1,218.1 | 251.2 | 28.1 | -- | 38.6 | 18.1 | |
| 985.8 | 9,643.7 | 1,286.4 | 79.6 | 15.9 | 4.7 | 123.2 | 4.1 | |
| 882.5 | 8,141.7 | 4,632.7 | 358.2 | 14.8 | 15 | 2.3 | 3.2 | |
| 689.6 | 5,552.1 | 696.5 | 188.0 | 34.5 | 19.8 | 29.5 | 5.6 | |
| 932.6 | 1,950.1 | 759.9 | 61.0 | 8.7 | 12.5 | 32 | 3.9 |
2 min read•By Research Desk
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties... segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It also offers anemia tablet and syrup, lycopene, minerals and vitamins capsules, products for eradication of vaginal pathogens, capsules for the treatment of menopause, herbal uterine tonic, syrup for the treatment lactation insufficiency, cough suppressants, liver tonic, medicine for burning urination, and nutritional supplements. In addition, the company engages in the trading of commodities and renting of properties. Further, it exports its products. The company offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India. Read more
Incorporated
1988
Chairman
Kedarmal Bankda
Managing Director
Vijay Shankarlal Bankda
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsAnnouncement Under Regulations 30 (LODR)
12-Jun-2025Announcement Under Regulation 30
05-Apr-2025
The total asset value of Syncom Formulations (India) Ltd stood at ₹ 413 Cr as on 31-Mar-25
The share price of Syncom Formulations (India) Ltd is ₹21.50 (NSE) and ₹21.50 (BSE) as of 13-Jun-2025 IST. Syncom Formulations (India) Ltd has given a return of 69.83% in the last 1 years.
Syncom Formulations (India) Ltd has a market capitalisation of ₹ 2,021 Cr as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Syncom Formulations (India) Ltd is 5.91 times as on 13-Jun-2025, a 6% premium to its peers’ median range of 5.57 times.
The P/E ratio of Syncom Formulations (India) Ltd is 40.88 times as on 13-Jun-2025, a 6% premium to its peers’ median range of 38.59 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Syncom Formulations (India) Ltd and enter the required number of quantities and click on buy to purchase the shares of Syncom Formulations (India) Ltd.
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It also offers anemia tablet and syrup, lycopene, minerals and vitamins capsules, products for eradication of vaginal pathogens, capsules for the treatment of menopause, herbal uterine tonic, syrup for the treatment lactation insufficiency, cough suppressants, liver tonic, medicine for burning urination, and nutritional supplements. In addition, the company engages in the trading of commodities and renting of properties. Further, it exports its products. The company offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
The prominent promoters of Syncom Formulations (India) Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
KEDARMAL SHANKARLAL BANKDA |
12.44%
|
|
VIJAY SHANKARLAL BANKDA |
10.48%
|
|
PARADISE VYAPAR PRIVATE LIMITED |
5.02%
|
|
ANKIT BANKDA |
4.99%
|
|
ASHA VIJAY BANKDA |
4.9%
|
The chairman of the company is Kedarmal Bankda, and the managing director is Vijay Shankarlal Bankda.
There is no promoter pledging in Syncom Formulations (India) Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,692
|
|
|
9,644
|
|
|
8,142
|
|
|
7,752
|
|
|
5,552
|
|
|
3,729
|
|
|
2,767
|
|
|
2,017
|
|
|
1,950
|
| Syncom Formulations (India) Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
15.08
|
|
Operating margin(%)
|
10.71
|
|
Net Margin(%)
|
10.25
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Syncom Formulations (India) Ltd was ₹49 Cr.
₹-0.35
(
